Arexera Therapeutics
PrivateLast Round
Series B
Jan 28, 2025
Total Funding Raised
$97M
Company Overview
Arexera Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in January 2025.
Arexera Therapeutics is a clinical-stage biotechnology company developing siRNA medicines for severe neurological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arexera Therapeutics Comparables
Compare Arexera Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Skyhawk Therapeutics | 87% | |
| Aerska | 83% | |
| Vico Therapeutics | 82% |
For institutional investors. Book with your work email.
Arexera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 28, 2025 | ||||
| Series A | Jan 11, 2021 |
For institutional investors. Book with your work email.
Arexera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series B |
| Mirae Asset | Series B |
| abrdn Inc. | Series B |
| Genentech | Series A |
| GHR Foundation | Series B |
| RiverVest Venture Partners | Series B |
| Pictet Alternative Advisors | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 28, 2025
$97M round led by Sanofi Ventures and EQT Life Sciences.
- Jan 11, 2021
Round led by F-Prime Capital with participation from Biogen and Genentech.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 20, 2026
Arexera develops a di-siRNA-based therapy targeting MSH3 for Huntington’s disease and also develops a candidate that targets HTT and MSH3 simultaneously in United States.
- is_developingOct 20, 2026
Arexera is developing a platform that delivers divalent siRNA (di-siRNA) molecules to cells deep within the brain, addressing the poor tissue delivery and rapid clearance associated with standard siRNA.
For institutional investors. Book with your work email.
Arexera Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Arexera Therapeutics's valuation, stock price, and market status.
Is Arexera Therapeutics a public or private company?
Arexera Therapeutics is a private company.
What is the current stock price of Arexera Therapeutics?
Arexera Therapeutics is a private company, so its shares have no public market price. Caplight tracks Arexera Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Arexera Therapeutics worth (valuation)?
Valuation information for Arexera Therapeutics is not publicly available.
Can I buy Arexera Therapeutics stock?
Arexera Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Arexera Therapeutics's last funding round?
Arexera Therapeutics's most recent funding round was Series B on January 28, 2025.
Who are the main investors in Arexera Therapeutics?
Key investors in Arexera Therapeutics include EQT Life Sciences, F-Prime Capital, Sanofi Ventures.
Will Arexera Therapeutics IPO soon?
No public IPO plans have been announced for Arexera Therapeutics.
How can I track Arexera Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Arexera Therapeutics's shares on secondary markets.